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Background: Evidence has suggested that periodontal disease is associated with an increased risk of various
adverse pregnancy and birth outcomes. However, several large clinical randomized controlled trials failed to
demonstrate periodontal therapy during pregnancy reduced the incidence of adverse pregnancy and birth
outcomes. It has been suggested that the pre-conception period may be an optimal period for periodontal disease
treatment rather than during pregnancy. To date, no randomized controlled trial (RCT) has examined if treating
periodontal disease before pregnancy reduces adverse birth outcomes. This study aims to examine if the
pre-conception treatment of periodontal disease will lead to improved periodontal status during late pregnancy
and subsequent birth outcomes.
Methods/Design: A sample of 470 (235 in each arm of the study) pre-conception women who plan to conceive
within one year and with periodontal disease will be recruited for the study. All participants will be randomly
allocated to the intervention or control group. The intervention group will receive free therapy including dental
scaling and root planning (the standard therapy), supragingival prophylaxis, and oral hygiene education. The control
group will only receive supragingival prophylaxis and oral hygiene education. Women will be followed throughout
their pregnancy and then to childbirth. The main outcomes include periodontal disease status in late pregnancy
and birth outcomes measured such as mean birth weight (grams), and mean gestational age (weeks). Periodontal
disease will be diagnosed through a dental examination by measuring probing depth, clinical attachment loss and
percentage of bleeding on probing (BOP) between gestational age of 32 and 36 weeks. Local and systemic
inflammatory mediators are also included as main outcomes.
Discussion: This will be the first RCT to test whether treating periodontal disease among pre-conception women
reduces periodontal disease during pregnancy and prevents adverse birth outcomes. If the effect of pre-pregnancy
periodontal treatment is confirmed, this intervention could be recommended for application in low- or middle-income
countries to improve both oral health and maternal and child health.
Trial registration: This trial is registered with Chinese Clinical Trial Registry (ChiCTR): ChiCTR-TRC-12001913.
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Periodontal disease is defined as an inflammatory condition
of the soft tissues surrounding the teeth (i.e., gingivitis) and
the destruction of the supporting structures of the teeth
[1-3]. As a persistent bacterial infection, periodontal disease
leads to a chronic and systemic challenge with bacterial
substances and host-derived inflammatory mediators that
are capable of initiating and promoting systemic diseases.
There is increasing evidence suggesting that periodontal
disease is associated with systemic diseases such as cardio-
vascular diseases, diabetes mellitus, as well as adverse preg-
nancy and birth outcomes [4-8].
The relationship between periodontal disease and
adverse birth outcomes
Since Offenbacher et al. first reported an association
between periodontal disease and preterm birth in 1996 [9],
substantial evidence has accumulated suggesting peri-
odontal disease may be associated with an increased
risk of various adverse pregnancy and birth outcomes such
as preterm birth, low birth weight, early pregnancy loss,
gestational diabetes and preeclampsia [10].
Inflammatory mediators induced by periodontal disease
have downstream effects on biological pathways and tissues.
Studies have shown increased levels of interleukin-1 beta
(IL-1β), IL-6, tumor necrosis factor alpha (TNF-α, beta-
glucuronidase (β–glucuronidase), prostaglandin E2 (PGE2),
aspartate aminotransferase (AST), metalloproteinase-8
(MMPT-8) and decreased level of osteoprotegerin (OPG)
not only in the gingival tissues, gingival cervicular fluid
(GCF), saliva, but also in the serum/ plasma of patients af-
fected by periodontal disease [2,11-19]. These inflammatory
mediators appear in the systemic circulation and eventually
cross the chorioamniotic barrier to finally appear in the
amniotic fluid. Additionally, maternal periodontal disease
results in placental and fetal exposure to microbes through
hematogenous dissemination. Blood-borne bacterial
products, especially lipopolysaccharide (LPS), target the
chorioamniotic plexus to trigger local PGE and TNF-α
synthesis. These host-derived inflammatory mediators urge
preterm membrane rupture and labor, resulting in preterm
delivery. This poor uteral environment could lead to fetal
growth restriction (FGR) and neonatal morbidity.
The optimal time for treating periodontal disease to
improve pregnancy outcomes
Attempts at treating periodontal disease during pregnancy to
achieve improved outcomes have had inconsistent conclu-
sions. Recently, several large clinical randomized controlled
trials failed to conclude that standard periodontal therapy
during pregnancy reduced the incidence of adverse preg-
nancy outcomes (e.g., preterm birth and low birth weight)
[20-22] The question of when to treat periodontal disease
was put forward.Pregnancy may not be an appropriate period for peri-
odontal disease treatment as discussed by Xiong et al.
[23]: 1) Treating periodontal disease during pregnancy
may be too late to reduce the local and systemic inflam-
mation activated by oral bacterial pathogens. 2) Dental
scaling and root planning during treatment itself may cause
bacteremia triggering systemic inflammation, leading
to adverse pregnancy and birth outcomes, 3) Because of
safety concerns on the frequency of periodontal treatment
during pregnancy, the treatments are often restrict to 1 or
2 courses, which may not be effective in preventing the
progression of periodontal disease.
In contrast, the pre-conception period may be optimal
for interventions [23]: 1) Pre-conception periodontal
therapy may lead to better outcomes as it can be more
intensive compared with treatment during pregnancy
(e.g., the use of adjunctive antibiotics). 2) Pre-conception
treatments may provide more evidence as to whether
periodontal disease is a causal risk factor for adverse preg-
nancy and birth outcomes (e.g. preterm birth et al.) 3) If
pre-conception periodontal treatment is shown to be
effective, it may highlight the biological mechanism of
how subclinical infections such as periodontal disease
lead to an increased risk of adverse pregnancy and birth
outcomes. 4) Periodontal disease is preventable and curable.
If the effect of pre-conception periodontal treatment is con-
firmed, this treatment will lead to improved pregnancy and
birth outcomes worldwide. Therefore, periodontal treatment
either before pregnancy (for nulliparous women) or in
the period between pregnancies (for multiparous women)
may reduce adverse pregnancy outcomes.
No randomized controlled trial (RCT) to date has exam-
ined if treating periodontal disease among pre-conception
women (e.g., women who plan to conceive within one year)
reduces the rate of adverse pregnancy or birth out-
comes. Therefore, we propose to conduct this RCT of
pre-conception treatment for periodontal disease to
improve periodontal status during pregnancy and birth
outcomes. In order to explore the biological mechanism
of periodontal disease and how it leads to increased risk
of adverse birth outcomes, we will also test and compare
the changes in inflammatory mediators mentioned above
in saliva, maternal blood and cord blood between the
intervention and control groups.
Objectives and hypotheses
The objective of the study is to examine if the pre-
conception treatment of periodontal disease leads to
the improved periodontal status during late pregnancy
and birth outcomes (e.g. mean birth weight and mean
gestational age).
We hypothesize that the pre-conception treatment
of periodontal disease (periodontal treatment one year
before pregnancy) will:
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pregnancy.
 Increase birth weight and prolong gestational
duration.
 Reduce mean levels of local and systematic
inflammatory mediators.
The primary outcome is periodontal disease determined
by measuring probing depth (PD), clinical attachment
loss (CAL) and percentage of bleeding on probing (BOP)
between 32 and 36 weeks of gestational age. Secondary out-
comes are mean birth weight (grams) and mean gestational
age (weeks). In addition, we will compare inflammatory
mediators (i.e. IL-1β, IL-6, β-glucuronidase, TNF-α, PGE2,
AST, MMP-8, OPG) in saliva, as well as in maternal blood
during late pregnancy and cord blood after delivery, in both
groups as secondary outcomes.
Methods/design
Overall study design
The design of this proposed study will be a randomized
controlled trial in which pre-conception women who plan
to conceive within one year will be eligible to participate in
an oral examination. Women who meet the criteria for
periodontal disease will then be randomized into two
groups: an intervention or periodontal treatment group,
versus a control group. All participants who get pregnant
within one year will be followed throughout their preg-
nancy (see Figure 1). Ethical approval to conduct the trial
has been granted by the Institutional Review Board of the
School of Public Health, Fudan University, Shanghai, China
(IRB# 2011-03-0271) and the study is registered with
Chinese Clinical Trial Registry (#ChiCTR-TRC-12001913).
Participants and recruitment
This RCT will be conducted at the Maternal and Child
Health Care Hospital, in Changzhou Municipality, China.
This hospital was chosen because it contained both
pre-conception consultation and dental clinics. Changzhou
is a medium sized city in eastern China, with a population
of 4,600,000 (in 2012). The hospital is the only maternal
and child health care hospital in Changzhou Municipality,
with a total of 9,000 deliveries annually (covering more than
70% of deliveries in the city).
Enrollment will be conducted among women attending
pre-conception health care counseling at the hospital. All
women attending pre-conception consultation clinics will
be approached by research assistants for their willingness
to participate in the study, and then will be assessed for
their eligibility to participate. Eligible women will be in-
vited to participate in a free full-mouth dental examin-
ation to screen for periodontal disease. Women who meet
the criteria for having periodontal disease will be in-
vited to participate in this trial and be randomized intothe intervention and control groups. Written informed
consent will be obtained from each participant before
the randomized group allocation is revealed.
Inclusion criteria
 Pre-conception women planning to conceive within
one year.
 At least 18 years old.
 Planning to deliver at the recruiting hospital.
Additional inclusion criteria for randomization:
 Diagnosed as having periodontal disease after a
dental examination.
 At least 20 teeth.
 Without moderate or severe dental caries.
 Without systemic or reproductive disease.
 Without rheumatoid arthritis.
 Without severe cardiovascular disease, diabetes,
hyperthyroidism, and/or other systemic diseases.
 Without immunodeficiency diseases.
 Willing to be compliant to follow up during the trial.
Exclusion criteria
 Less than 18 years old.
 Fewer than 20 teeth.
 Contraindication to probing in a dental examination
and treatment, such as heart disorders.
 Unwilling or unable to sign the informed consent form.
 Receiving periodontal treatment within the past six
months.
 Changing pregnancy plan (no plan to be pregnant
within a year).
 With a disease mentioned in the inclusion criteria.
Sample size
Sample size calculation for primary outcomes
We calculated that a consecutive sample of 470 (235 in
each arm of the study) pre-conception women with peri-
odontal disease will be required for the study. The sample
size calculation is based on detecting changes in primary
outcome of periodontal disease measurements- probing
depth (PD) and clinical attachment loss (CAL) in millime-
ters (mm). To detect a difference in mean PD of 0.15 mm
between the groups in the 3rd trimester, a sample size
of 141 for per group is needed. This was based on an
estimated mean PD of 1.6 mm and SD of 0.2 mm from
the earlier pilot study of 53 pre-conception women
(mean PD of cases = 2.0 mm, SD = 0.3 mm; mean PD of
non-cases = 1.8 mm, SD = 0.4 mm). After allowing for
an estimated 25% exclusion due to non-pregnancy at the
end of the first year and 20% loss to follow up during
Pre-conception women
(at pre-conception health care consultation clinic)
Baseline dental examination (at dental clinic); 
Maternal saliva and blood sample collection
Randomization
Intervention group:
• local scaling and root planning (deep  
cleaning)
• supragingival prophylaxis
• oral hygiene education 
Control group:
• supragingival prophylaxis
• oral hygiene education
3rd trimester (32-35 weeks)
Final dental examination; Maternal saliva and blood sample collection




Figure 1 Research flow chart.
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women with periodontal disease. With the estimation of
55% prevalence of periodontal disease (from the pilot study),
854 pre-conception women will be recruited for screening
periodontal disease to identify 470 women with periodontal
disease. The sample size calculation based on CAL is
the same as the calculation using PD.
Calculation of statistical power for secondary outcomes
The power calculations for secondary outcomes include
mean birth weight, mean gestational age, and levels of
selected inflammatory mediators in the 3rd trimester.
Mean birth weight Given the initial sample size of 141
in each group for detecting differences in PD and CAL
measurements between the intervention and control groups,
the proposed study will have 99.7% statistical power to
detect a difference in birth weight of 200 g, with a SD
400 g and 300 g in each group respectively, at 0.05 sig-
nificance level.
Mean gestational week Given the sample size of 141 in
each group, the proposed study will have 86.9% statisticalpower to detect a difference in gestational week of 0.5 week
between two groups, with SD 1.5 week and 1.2 week in
each group respectively, at 0.05 significance level.Selected mean biological markers Given the sample
size of 141 in each group, the proposed study will have
statistical power ranging from 89.2% to 99.9% to detect
differences in the selected mean biological markers in-
cluding AST, TNF-α, IL-1β, IL-6, MMP-8 at 0.05 signifi-
cance level [18,24-26].Enrollment and randomization procedures
Random allocation to either the intervention or control
group is concealed by sequentially numbered, sealed
opaque envelopes containing the group allocation,
which will be determined by a computer generated
random number. A research group member who has
no direct contact with participants will be responsible
for generating the random numbers and preparing the
envelopes. Immediately after the dental examination,
the nurse will open the sealed envelope and inform
the participant of the group allocation.
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Women in the intervention group will be provided
with free treatment for periodontal disease. The peri-
odontal therapy includes local scaling and root planning
(standard therapy), supragingival prophylaxis, plus oral
hygiene education (e.g., tooth brushing instructions).
After the initial treatment, women in the intervention
group will be requested to have re-examination and re-
treatment every three months until they become pregnant.
All of the examination, treatment and health education will
be free. Once women are identified as pregnant, treatment
will be stopped.
Control group
Women in the control group will not receive the same local
therapy but will instead receive supragingival prophylaxis,
plus oral hygiene education. They will be advised to have
re-examination every three months in the following year. In
the 3rd trimester, women in the control group will be asked
to have a periodontal examination.
Data collection
Baseline data
Prior to the periodontal examination, a questionnaire
will be administered to collect information such as demo-
graphics, socio-economic status, medical history, and use of
dental care, etc.
Periodontal disease measurements
The initial pre-conception periodontal examination will
be recorded and will reflect the baseline periodontal sta-
tus. Measurements will be taken at six sites per tooth
(Mesio-buccal, mesio-lingual, disto-buccal, disto-lingual,
mid-buccal and mid-lingual), using a manual UNC-15
probe [3]. There is no universally accepted research
definition for the diagnosis of periodontal disease. In
previous studies, definitions that combined PD and CAL
over a certain threshold were used [3,10]. PD was defined
as the distance in millimeters from the gingival margin to
the apical part of the pocket. CAL represents the distance
between the cemento-enamel junction (CEJ) and the base
of the pocket. CAL is obtained by adding the PD meas-
urement to the recession that is the distance between
the CEJ and the gingival margin. In this study, periodontal
disease was defined as a presence of any sites exhibiting
PD > 3 mm or CAL > 3 mm.
All periodontal measurements will be performed by
one dentist who will be blinded to the group allocation
of pre-conception women to ensure study reliability.
Another dentist will be responsible for periodontal the-
rapy, supragingival prophylaxis and oral health education.
A dental nurse will record the scores on clinical periodon-
tal indexes including PD, BOP and recession of each site
for each woman during the oral examination.Prior to the enrollment of patients in the study, dentists
will be invited to participate in a calibration study. During
this section, three healthy volunteers will be recruited and
will be examined by dentists and an experienced periodon-
tist. Inter- and intra-examiner variations in periodontal
probing measurements (e.g., PD, recession) will be iden-
tified between and among dentists and the experienced
periodontist. They will discuss the difference and adjust
the measurement approach until a final agreement is
reached. After calibration, intra- and inter-examiners’
agreement rates of PD measurements within ± 1 mm
should be reached. Kappa statistic and intra-class corre-
lation coefficient among dental examiners for the studies
will be calculated.
The last dental examination will be carried out in the
3rd trimester as the final evaluation data.
Biologic sample collection
Saliva collection We choose saliva samples to reflect
periodontal health instead of gingival cervicular fluid
(GCF) due to the following advantages: (1) Compared
with GCF sampling, saliva sampling is convenient and
simple. (2) The concentration of salivary components
from the analysis reflects progression and severity of
periodontal disease. (3) The level of the ingredients in
saliva may provide evidence for the need for further
treatment and the effect of treatment response. (4) Saliva
reflects the overall periodontal health of the patient,
rather than at a point [27,28].
In this study, saliva will be collected before the initial
pre-conception dental examination and prior to the last
examination in the 3rd trimester. We collected whole ex-
pectorated saliva, without stimulation, from each partici-
pant using an adapted version of the method described by
Miller et al. [2]. Women will be asked to rinse their mouths
with tap water, wait for 5 minutes, and then expectorate
whole saliva into sterile tubes. The samples will be immedi-
ately centrifuged, and the upper clear portion will be kept
and frozen at −80°C.
Blood sample collection During women’s routine blood
draws at both their pre-conception health care visit and
their antenatal visit in the 3rd trimester, 5 ml extra blood
will be collected from each woman and kept at −80°C
for the proposed study.
Cord sample collection Immediately after delivery, 5 ml
cord blood will be collected and kept in −80°C.
Birth outcomes Reviews of medical records will be
conducted by the research nurse to record birth weight
and gestational age. Pregnancy history, birth outcomes,
as well as adverse events will be documented using a
uniformed form.
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Given the nature of the intervention, participants will not
be blinded to their group allocation. To minimize bias, the
dentist who is going to perform the baseline and final
periodontal examination will be blinded. All treatments
and oral health care will be carried out by another dentist.
Furthermore, researchers who collect biological samples
will be blinded to the allocation of women’s group.
All materials containing individual information of partici-
pants will be stored in a locked cabinet and only accessible
to research team members. The computer with research
information and data will be password protected and only
be accessed by authorized research team members.
Data analysis plan
All analyses will be conducted with “intention to treat”
analysis [29]. Descriptive statistics will be performed to
examine for all exposures, outcomes and covariates. For
continuous variables, such as PD, CAL, birth weight
(grams), gestational age (weeks), biologic parameters,
means will be compared using t-tests, or non-parametric
equivalents for non-normally distributed variables. For ca-
tegorical variables such as the rate of periodontal disease,
chi-squared tests will be used. The outcomes will be com-
pared between the intervention and control groups, and
between pregnancy and pre-conception groups.
Data safety monitoring plan
To ensure the safety of research participants and the vali-
dity and integrity of data, we will develop a Data Safety
Monitoring Plan and establish an independent Data Safety
and Monitoring Board (DSMB). The primary responsibilities
of the DSMB are to develop protocol stopping guidelines
related to the safety of individuals and the overall trial.
Discussion
To our knowledge, this is the first study developed to test
the efficacy of pre-conception periodontal disease treatment
in the prevention of adverse birth outcomes. The pre-
conception periodontal treatment mainly includes scaling
and root planning (standard therapy) in combination with
personal oral hygiene. These are non-surgical periodontal
procedures and can be performed by oral health profes-
sionals (e.g., dentists or dental hygienists) after receiving ap-
propriate training. In addition, since periodontal treatment
is performed before pregnancy, it will avoid potential risks
to the pregnancy (fetus) and will be less stressful to women.
If the intervention is effective, it will be more acceptable
by women and society, and have potential generalizability.
Furthermore, the study will help develop a model of pre-
conception oral health care to improve both oral health
and maternal and child health nationally and internation-
ally. The pre-conception periodontal treatment strategy
may be applicable to many low-or middle-income countries(e.g., India and China), where childbearing aged and
pregnant women have no or limited access to preventive
or restorative dental care.
Due to the limited funding resource, the sample size of
this study is relatively small, which may not allow for the ob-
servation of some pregnancy outcomes e.g. rate of preterm
birth and low weight birth, rate of gestational diabetes, rate
of preeclampsia, and other birth outcomes. If there is evi-
dence of effectiveness after this initial study, we will seek fur-
ther funding to expand the trial, with pregnancy and birth
outcomes (e.g. rate of low birth weight and preterm birth)
as primary outcomes.
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